Sanofi Will Need More Trials to Set New Asthma Drug Apart from Rival
Dow Jones
Sep 09
1250 GMT - Sanofi's results from a midstage study for a new asthma drug look positive, but more data will be needed to establish whether the medicine has a differentiated profile relative to a rival treatment, Citi analysts say in a research note. Results presented by the French drugmaker at a medical conference show its experimental lunsekimig asthma drug achieved a clinical benefit in a midstage study, but a late-stage trial will be needed to determine whether it beats AstraZeneca's Tezspire, the analysts say. Citi estimates lunsekimig could reach annual sales of 1.8 billion euros at its peak across asthma and chronic obstructive pulmonary disease. Sanofi shares fall 1.1%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.